Ada Gjyrezi
Overview
Explore the profile of Ada Gjyrezi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galletti G, Halima A, Gjyrezi A, Zhang J, Zimmerman B, Worroll D, et al.
medRxiv
. 2024 Jul;
PMID: 38947080
One Sentence Summary: Transferrin Receptor identifies circulating tumor cells in solid tumors.
2.
Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al.
Commun Biol
. 2021 Jun;
4(1):785.
PMID: 34168263
Quantitation of androgen receptor variant (AR-V) expression in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) has great potential for treatment customization. However, the absence of...
3.
Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, et al.
J Clin Invest
. 2020 Jun;
130(6):3287-3298.
PMID: 32478682
Despite widespread use of taxanes, mechanisms of action and resistance in vivo remain to be established, and there is no way of predicting who will respond to therapy. This study...
4.
Galletti G, Zhang C, Gjyrezi A, Cleveland K, Zhang J, Powell S, et al.
Clin Cancer Res
. 2020 Apr;
26(14):3771-3783.
PMID: 32321717
Purpose: Although taxane-based therapy is standard treatment for advanced gastric cancer, a majority of patients exhibit intrinsic resistance to taxanes. Here, we aim to identify the molecular basis of taxane...
5.
Tagawa S, Antonarakis E, Gjyrezi A, Galletti G, Giannakakou P
Clin Cancer Res
. 2019 Oct;
25(19):6010-6011.
PMID: 31575715
No abstract available.
6.
Worroll D, Galletti G, Gjyrezi A, Nanus D, Tagawa S, Giannakakou P
Phys Biol
. 2019 Feb;
16(3):036003.
PMID: 30763921
Androgen receptor (AR) signaling drives prostate cancer (PC) progression and remains active upon transition to castration resistant prostate cancer (CRPC). Active AR signaling is achieved through the nuclear accumulation of...
7.
Tagawa S, Antonarakis E, Gjyrezi A, Galletti G, Kim S, Worroll D, et al.
Clin Cancer Res
. 2018 Oct;
25(6):1880-1888.
PMID: 30301829
Purpose: Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR, in mCRPC patient circulating...
8.
Antonarakis E, Tagawa S, Galletti G, Worroll D, Ballman K, Vanhuyse M, et al.
J Clin Oncol
. 2017 Jun;
35(28):3181-3188.
PMID: 28632486
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes...
9.
Darshan M, Loftus M, Thadani-Mulero M, Levy B, Escuin D, Zhou X, et al.
Cancer Res
. 2011 Jul;
71(18):6019-29.
PMID: 21799031
Prostate cancer progression requires active androgen receptor (AR) signaling which occurs following translocation of AR from the cytoplasm to the nucleus. Chemotherapy with taxanes improves survival in patients with castrate...
10.
Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, et al.
ACS Nano
. 2011 Jul;
5(8):6184-94.
PMID: 21728341
Resistance to chemotherapy is a major obstacle in cancer therapy. The main purpose of this study is to evaluate the potential of a folate receptor-targeting nanoparticle to overcome/minimize drug resistance...